Ixazomib – the first oral proteasome inhibitor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ixazomib – the first oral proteasome inhibitor

Published:2019-01-07 Issue:3 Volume:60 Page:610-618
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Xie Jingmei¹,Wan Ning²³,Liang Zhuoru¹,Zhang Tiantian¹,Jiang Jie¹⁴

Affiliation:

1. College of Pharmacy, Jinan University, Guangzhou, PR China;

2. Department of Pharmacy, Guangzhou General Hospital of Guangzhou Military Command, PR China;

3. Guangzhou Huabo Biopharmaceutical Research Institute, PR China;

4. Dongguan Institute of Jinan University, Dongguan, PR China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province, China

Fundamental Research Funds for the Central Universities

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1523398

Reference43 articles.

1. SnapShot: Multiple Myeloma

2. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016

3. Novel agents in the treatment of multiple myeloma: a review about the future

4. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses

5. Multiple Myeloma

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022;Pharmaceuticals;2024-06-21

2. Combined green analytical principles and quality by design for ultraperformance liquid chromatography analytical method development, the characterization and in-silico toxicity prediction of Ixazomib degradation products using mass spectrometry;Green Analytical Chemistry;2024-03

3. Evolution of Natural Product Scaffolds as Potential Proteasome Inhibitors in Developing Cancer Therapeutics;Metabolites;2023-03-31

4. Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma;Neuro-Oncology;2023-02-20

5. Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma;International Journal of Molecular Sciences;2023-01-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3